Magnolol inhibits cancer stemness and IL-6/ Stat3 signaling in oral carcinomas

doi:10.1016/j.jfma.2021.01.009

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23283

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23283

题名:	Magnolol inhibits cancer stemness and IL-6/ Stat3 signaling in oral carcinomas
作者:	Peng, CY;Yu, CC;Huang, CC;Liao, YW;Hsieh, PL;Chu, PM;Yu, CH;Lin, SS
关键词:	Oral squamous cell carcinomas;Magnolol;Cancer stem cells
日期:	2021
上传时间:	2022-08-05T09:34:45Z (UTC)
出版者:	ELSEVIER TAIWAN
ISSN:	0929-6646
摘要:	Background/purpose: Cancer stem cells (CSCs) have been known to be implicated in tumori-genesis, metastasis, and drug resistance in oral squamous cell carcinomas (OSCC). In this study, we aimed to investigate whether magnolol, a polyphenolic component derived from Magnolia officinalis, exhibited the anti-CSCs properties. Methods: The cytotoxicity of magnolol was tested using normal gingival epithelioid SG cells and sphere-forming OSCC-CSCs isolated from SAS, OECM1, and GNM cells. Secondary sphere-forming ability, the proportion of ALDH1 positive cells, Transwell migration, and invasion ca-pacities were examined as well. The chemosensitive effects of magnolol were investigated us -ing MTT, secondary sphere-forming, and invasion assays. Results: Magnolol exerted a higher cytotoxicity of OSCC-CSCs and cancer stemness features, including self-renewal ability, the expression CSC marker, migration, and invasion capacities were all downregulated in magnolol-treated OSCC-CSCs. Moreover, administration of magnolol potentiated the effect of cisplatin, including a decrease in cell viability, self-renewal, and in-vasion activities. In addition, we observed that the secretion of IL-6 and phosphorylation of Stat3 were decreased in OSCC-CSCs treated with magnolol. Conclusion: Our data suggest that magnolol is able to target CSCs and suppress the cancer stemness properties, at least in part, via IL-6/Stat3 signaling. Besides, a dietary supplement of magnolol may function as an adjunct to cisplatin treatment. Copyright 2021, Formosan Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
URI:	http://dx.doi.org/10.1016/j.jfma.2021.01.009 https://www.webofscience.com/wos/woscc/full-record/WOS:000732498800007 https://ir.csmu.edu.tw:8080/handle/310902500/23283
關聯:	JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION ,2022,v121,issue 1, P51-57
显示于类别:	[中山醫學大學研究成果] 期刊論文

文件中的档案:

档案	描述	大小	格式	浏览次数
index.html		0Kb	HTML	180	检视/开启

在CSMUIR中所有的数据项都受到原著作权保护.

TAIR相关文章

数据加载中.....